Literature DB >> 17571068

"Getting the dose right": facts, a blueprint, and encouragements.

C C Peck1, J T Cross.   

Abstract

Mesh：

Substances：

Year:  2007        PMID： 17571068     DOI： 10.1038/sj.clpt.6100215

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  10 in total

1.  Delivered dose: a drug-centric phenotype for chemotherapy dose individualization.

Authors:  Y Bruce Yu
Journal:  Pharm Res       Date:  2009-06-03       Impact factor: 4.200

Review 2.  Pharmacokinetic and pharmacodynamic data to be derived from early-phase drug development: designing informative human pharmacology studies.

Authors:  Adam Cohen
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

3.  Evaluation of agile designs in first-in-human (FIH) trials--a simulation study.

Authors:  Itay Perlstein; James A Bolognese; Rajesh Krishna; John A Wagner
Journal:  AAPS J       Date:  2009-09-16       Impact factor: 4.009

4.  First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer.

Authors:  Mark P S Dunphy; Christina Pressl; Nagavarakishore Pillarsetty; Milan Grkovski; Shanu Modi; Komal Jhaveri; Larry Norton; Bradley J Beattie; Pat B Zanzonico; Danuta Zatorska; Tony Taldone; Stefan O Ochiana; Mohammad M Uddin; Eva M Burnazi; Serge K Lyashchenko; Clifford A Hudis; Jacqueline Bromberg; Heiko M Schöder; Josef J Fox; Hanwen Zhang; Gabriela Chiosis; Jason S Lewis; Steven M Larson
Journal:  Clin Cancer Res       Date:  2020-05-04       Impact factor: 12.531

5.  Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization.

Authors:  Elisabet I Nielsen; Otto Cars; Lena E Friberg
Journal:  Antimicrob Agents Chemother       Date:  2011-08-01       Impact factor: 5.191

6.  Dosimetry of 18F-labeled tyrosine kinase inhibitor SKI-249380, a dasatinib-tracer for PET imaging.

Authors:  Mark P S Dunphy; Pat Zanzonico; Darren Veach; Romel Somwar; Nagavarakishore Pillarsetty; Jason Lewis; Steven Larson
Journal:  Mol Imaging Biol       Date:  2012-02       Impact factor: 3.488

7.  Dose Optimization of Cefpirome Based on Population Pharmacokinetics and Target Attainment during Extracorporeal Membrane Oxygenation.

Authors:  Jin Wi; Min Jung Chang; Soyoung Kang; June Young Jang; Jongsung Hahn; Dasohm Kim; Jun Yeong Lee; Kyoung Lok Min; Seungwon Yang
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

Review 8.  Application of PK/PD Modeling in Veterinary Field: Dose Optimization and Drug Resistance Prediction.

Authors:  Ijaz Ahmad; Lingli Huang; Haihong Hao; Pascal Sanders; Zonghui Yuan
Journal:  Biomed Res Int       Date:  2016-02-16       Impact factor: 3.411

9.  Efficacy and Safety of Eravacycline in Obese Patients: A Post Hoc Analysis of Pooled Data From the IGNITE1 and IGNITE4 Clinical Trials.

Authors:  Tomefa E Asempa; Sergey Izmailyan; Kenneth Lawrence; David P Nicolau
Journal:  Open Forum Infect Dis       Date:  2020-11-13       Impact factor: 3.835

Review 10.  The Unique Pharmacometrics of Small Molecule Therapeutic Drug Tracer Imaging for Clinical Oncology.

Authors:  Mark P S Dunphy; Nagavarakishore Pillarsetty
Journal:  Cancers (Basel)       Date:  2020-09-22       Impact factor: 6.639
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.